OncoAssure Prostate Demonstrates Superior Prognostic Value at AUA 2026

New data presented at AUA 2026 in Washington, DC (Abstract IP31-22) show that OncoAssure Prostate, a six-gene Molecular Clinical Risk Score (MCRS), outperforms standard NCCN and CAPRA risk models in men with clinically low-risk prostate cancer. In a study of 233 patients from Irish and Swedish cohorts, the MCRS was significantly more prognostic for adverse pathology, high primary Gleason grade, and biochemical recurrence, and added value when combined with clinical assessment. Decision curve analysis confirmed greater net clinical benefit, supporting OncoAssure Prostate as a tool to better identify candidates for active surveillance versus treatment.